CLOs on the Move

Betsy Johnson Regional Hospital

www.bjrh.org

 
Betsy Johnson Regional Hospital is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Betsy Johnson Regional Hospital is based in Dunn, NC. You can find more information on Betsy Johnson Regional Hospital at www.bjrh.org
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

AllMed

AllMed Healthcare Management is a utilization management and independent review organization providing comprehensive nurse and physician review solutions to payer and provider organizations nationwide. Our clients include leading health plans, medical management organizations, TPAs, disability carriers, hospital groups and ambulatory surgery centers. Services are deployed through PeerPoint, AllMed`s state-of-the-art medical review portal.

Optics Institute of Southern California

Optics Institute of Southern California is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LKIS Corporation

LKIS Corporation is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Martech Medical Products

Martech Medical Products is a Harleysville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.